HomeFilePharmacology

Pharmacology

View Category

Other

ESC 2021 | GREENNESS: Surprising New Protective Factor against Cardiovascular Disease

What Is “Greenness”? This factor—which generally refers to the proximity to vegetation, as measured by satellite pictures—could...
solaci -
Learn More
Other

ESC 2021 | Empagliflozin in Heart Failure with Reduced and Preserved Ejection Fraction

The full results of the EMPEROR-Preserved study confirm as findings that empagliflozin decreases the risk of death...
solaci -
Learn More
Acute coronary syndromes

ESC 2021 | ISAR-REACT 5: Prasugrel Superior to Ticagrelor in ACS across Kidney Function Spectrum

When we have to choose between two potent P2Y12 receptor inhibitors for a patient undergoing ACS with...
solaci -
Learn More
Antiplatelet

ESC 2021 | MASTER DAPT: Dual Antiplatelet Therapy After Coronary Angioplasty in Patients at High Bleeding Risk

Courtesy of Dr. José Álvarez. In patients at high bleeding risk with drug-eluting stents, the duration of dual...
solaci -
Learn More
Acute coronary syndromes

Dual Antiaggregation De-Escalation: A New Paradigm?

De-escalating dual antiaggregation could be the most effective strategy after acute coronary syndrome seeing as it prevents...
solaci -
Learn More
Acute coronary syndromes

The Role of Aspirin after the TWILIGHT-ACS

This analysis corroborates the potential benefit of ticagrelor monotherapy following a short period of dual antiaggregation (DAPT)...
solaci -
Learn More
Acute coronary syndromes

Ticagrelor or Prasugrel for Acute Patients Who Undergo Angioplasty

We are still asking the same question: ticagrelor or prasugrel? With narrow margins between these drugs in...
solaci -
Learn More
Other

Polypharmacy in Older Adults Elderly: What Medication to Discontinue

Polypharmacy is certainly a problem in the elderly population. Forgetfulness, and drug and dose confusion can lead...
solaci -
Learn More